Sigilon Hemophilia Cell Therapy On Clinical Hold, But May Not Be Drug-Related
SIG-001 Seen As Potential Competitor To AAV Gene Therapies
Executive Summary
A patient developed Factor VIII inhibitors, but he had also recently received a COVID-19 vaccine and was genetically predisposed.